Biopharmaceuticals

Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann

NEW YORK, Aug. 4 /PRNewswire-FirstCall / -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) announced today that the Company and Alfa Wassermann S.p.A. have settled a dispute over issues arising from the terminated license agreement for Sulonex (sulodexide). Under the terms of the settl...

Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma

NEW YORK, Aug. 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathw...

Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements

NEW YORK, June 17 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) announced today that the Company has received a letter from The NASDAQ Stock Market confirming that it has regained compliance with the minimum bid price requirement for continued listing on The NASDAQ Cap...

Keryx Biopharmaceuticals Receives Nasdaq Notification

NEW YORK, Nov. 21 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced that on November 17, 2008, it received notice from The Nasdaq Stock Market ("Nasdaq") stating that the Company is no longer in compliance with Marketplace Rule 4310(c)(3), which requires th...

Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis

LONDON, Oct. 29 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel, anti-inflammatory drugs, announced today the preliminary results from its recently completed Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 10...

XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007

VALLEY COTTAGE, N.Y., March 20 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB ; TASE: XTL), a biopharmaceutical company engaged in the acquisition and development of therapeutics for the treatment of unmet medical needs, particularly diabetic neuropathic pain and hepatiti...

Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG

ROCKVILLE, Md., Dec. 4 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI ) announced today that it has completed the sale of assets constituting its Biologics strategic business unit (SBU) to Biotest Pharmaceuticals Corporation, a wholly-owned subsidiary of Biotest AG, for $185 ...

Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting

Improved Financial Performance Continues; Stockholders Approve Sale of Nabi Biologics to Biotest BOCA RATON, Fla., Nov. 8 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI ) today announced its third quarter financial results. The company recorded a net lo...

Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference

Corrected Announcement Follows NEW YORK, Oct. 2 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced that I. Craig Henderson, MD, the Company's President, will present an overview of the Company's cancer pipeline at the upcoming William...

New lease of life for asthmatics by Accentia Biopharmaceuticals

Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), through its specialty pharmaceuticals subsidiary, TEAMM Pharmaceuticals, Inc., has developed MD Turbo.// It is the first and only available product that transforms many of the most commonly prescribed metered dose inhalers (MDIs) into breath-activat...

Biopharmaceuticals in Medical Technology

Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

KRX-0401 + Capecitabine More Than Doubles Time to Progression and Overall Response Rate as well as Extends Overall Survival vs. Capecitabine + Placebo in Patients with 2nd or 3rd Line Metastatic Colon Cancer NEW YORK, June 1 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasda...

Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

KRX-0401 + Capecitabine More Than Doubled Time to Progression and Overall Response Rate as well as Extended Overall Survival vs. Capecitabine + Placebo in Patients with 2nd or 3rd Line Metastatic Colon Cancer NEW YORK, May 31 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: ...

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

KRX-0401 Demonstrates Impressive Single Agent Efficacy in Patients who Progressed after Failing Treatment Either with a VEGF Receptor Inhibitor or after Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor NEW YORK, May 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, I...

XTL Biopharmaceuticals Announces the Acquisition of the Use Patent on Recombinant Erythropoietin (rHuEPO) for the Treatment of Multiple Myeloma

REHOVOT, Israel, March 18 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB ; TASE: XTL) announced today that it has entered into an asset purchase agreement with Bio-GAL Ltd, a private company, for the rights to a use patent on Recombinant Erythropoietin ("rHuEPO") for the...

XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain

VALLEY COTTAGE, N.Y., June 30 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB ; TASE: XTL) today announced that it has completed patient randomization into its Phase 2b study of Bicifadine -- a serotonin and norepinephrine reuptake inhibitor (SNRI) -- for the treatment of ...

Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis

LONDON, June 24 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced that it has initiated a Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from all...

Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis

LONDON, June 11 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced that it has obtained regulatory approval from the South African Medicines Control Council (MCC) to initiate a Phase II study o...

Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial

NEW YORK, March 27 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) announced today that following a Drug Safety and Monitoring Committee (DSMC) review of the SUN-MACRO Phase 4 trial of Sulonex(TM) (sulodexide oral gelcap), the Company has decided to terminate the stud...

Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint

Company to host a conference call Monday, March 10, 2008 at 8:30am NEW YORK, March 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced top-line results from its SUN-MICRO Phase 3 clinical trial of Sulonex (sulodexide) for the treatment of diabetic nep...

Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial

NEW YORK, Feb. 11 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals announced today that the last subject randomized into the SUN-Micro Phase 3 clinical trial has completed their scheduled 8 month visit. This milestone officially marks the completion of this pivotal clinical trial of its inve...

Biopharmaceuticals in Biological News

Toxicology program features wide range of human health and environment topical sessions

...with sessions addressing such topics as neurodegenerative disease, engineered nanomaterials, inflammation, preclinical evaluation of cancer hazard and biopharmaceuticals and two lectures by Nobel laureates Dr. Aaron Ciechanover who will lecture on cellular mechanisms of protein degradation and Dr. Paul Greengard who wi...

Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics

...etastatic colorectal cancer. Of all the larger integrated healthcare companies, Roche has best executed the synergies of molecular diagnostics and biopharmaceuticals and is well positioned for the future with products in oncology and infectious disease. Its genetic tests include CYP450 for drug metabolism studies a...

ASNTR 15th anniversary meeting to be held May 1-3 in Florida

... same Web site. Celebrating its 15th anniversary in 2008, the ASNTR is the pre-eminent society focused on cell therapy, stem cells, gene therapy and biopharmaceuticals for neurological injury and disease. Society attendees specialize in translating pre-clinical and clinical research to the development of novel thera...

Biopharmaceutical infrastructure key to lower drug development costs

...vements to the technology infrastructure for researching and developing new biopharmaceuticals would be expected to save the industry hundreds of millions of dollars annu... shifted from small-molecule chemicals to large-molecule proteins and other biopharmaceuticals such as human insulin, gene therapies and specialized antibiotic treatments...

Using green chemistry to deliver cutting-edge drugs

...use high temperatures and harsh solvents damaging the active components of biopharmaceuticals before they have even reached the patient. But using green chemistry techni...rug delivery devices because it means that patients will be able to receive biopharmaceuticals which do not survive conventional chemical processing because they are eith...

SinuNase Phase 3 show almost 100 percent of chronic sinusitis cases are from fungal-induced inflamma

... TAMPA, Fla.September 10, 2007--Accentia biopharmaceuticals (NASDAQ: ABPI) announces evidence that most, if not all cases of chronic si...ase will be the first therapy available to treat sufferers of CS. Accentia biopharmaceuticals is commercializing SinuTest for the confirmation of CS. Investigators at Ma...

Modified mushrooms may yield human drugs

...Penn State. "Mushrooms could make the ideal vehicle for the manufacture of biopharmaceuticals to treat a broad array of human illnesses. But nobody has been able to com...y of other factors, but researchers point out that the process of producing biopharmaceuticals is potentially faster and cheaper with mushrooms than conventional technolo...

Killing brain tumors from within: A 'Trojan horse' approach

... recent article in the journal PLOS Medicine. Further testing is planned in a clinical setting. In the meantime, a small start-up company, Algen biopharmaceuticals Ltd., has been established through the Hebrew University's Yissum Technology Transfer Company to promote commercial development of the new drug. Prof...

Smokers invite to test vaccine against nicotine addiction

...is designed to help smokers quit and to limit the urge to start smoking again. Called NicVax, the investigational vaccine is being developed by Nabi biopharmaceuticals to prevent and treat nicotine addiction and to help people quit smoking. Normally when a smoker inhales, nicotine is carried by the bloodstream to the...

Rensselaer researchers develop approach that predicts protein separation behavior

...on applications, such as the protein purification methods used in drug discovery. This could potentially reduce the development time required to bring biopharmaceuticals to market." The modeling technique is based on methods previously developed by Breneman's group for rapidly predicting the efficacy and side effe...

Biopharmaceuticals in Biological Technology

Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University

PALO ALTO, Calif., August 4, 2009 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that it has licensed the exclusive worldwide rights to novel Hepatitis C Virus (HCV) technology from Stanford University. This te...

Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting

LAGUNA NIGUEL, Calif., July 14 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of positive preclinical safety, toxicology and preliminary pharmacokinetic data on its lead product, IB1001, a novel recombinant Factor IX product to treat patients with he...

Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients

NEW YORK, June 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced results of the Phase 2 study of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on thri...

Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer

NEW YORK, May 20 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (the "Company") (Nasdaq: KERX ) announced today the appointment of Ron Bentsur as Chief Executive Officer of the Company. It is also anticipated that Ron Bentsur will join the Company's Board of Directors at the annual mee...

Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology

Results Will be Reported from Phase 2 Studies Evaluating KRX-0401 in Advanced Renal Cell Carcinoma, Colorectal Cancer and Gastrointestinal Stromal Tumors (GIST) NEW YORK, May 18 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced that four abstracts on ...

Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research

Data Selected for Presentation Highlights Anti-Tumor effects of KRX-0401 (Perifosine) NEW YORK, April 21 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced multiple presentations of preclinical data highlighting the anti-tumor effects of KRX-0401 (perif...

XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel

REHOVOT, Israel, April 16 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB , TASE: XTL) today announced that on April 15, 2009, it received notification from The Nasdaq Stock Market ("Nasdaq") that the Nasdaq Listing Qualifications Panel (the "Panel") has determined that t...

The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan

LONDON, March 18 /PRNewswire/ -- Despite the initial regulatory hiccups, the number of biosimilars in the European market is set to increase gradually. The patent expiry of key biopharmaceuticals has opened up numerous lucrative market opportunities, while driving the development of biosimilars. I...

XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009

VALLEY COTTAGE, N.Y., March 11 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB ; TASE: XTL) announced today that its Extraordinary General Meetings ("EGMs") were postponed for one week in accordance with its articles of association due to the absence of a quorum. The postpone...

Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification

Unless appealed, delisting scheduled for March 12, 2009 NEW YORK, March 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced that it received a letter from the Staff of The Nasdaq Stock Market indicating that the Company had failed to regain compliance...

Biopharmaceuticals in Biological Dictionary

Sequencing

...ram. Bioenergy at DOE JGI. Tours. Historical Timeline. Assembly Exercise ... At JGI, we use whole-genome shotgun sequencing . ... Sequencing for biopharmaceuticals Glossary & taxonomy ... Sequencing DNA is only a first step towards ... Sequencing of carbohydrates is even more difficult. ... sequen...